Trexquant Investment LP Buys 43,193 Shares of Pfizer Inc. (NYSE:PFE)

Trexquant Investment LP grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 765,736 shares of the biopharmaceutical company's stock after purchasing an additional 43,193 shares during the quarter. Trexquant Investment LP's holdings in Pfizer were worth $20,315,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Centric Wealth Management grew its stake in shares of Pfizer by 175.1% in the 4th quarter. Centric Wealth Management now owns 85,997 shares of the biopharmaceutical company's stock valued at $2,282,000 after buying an additional 54,736 shares during the period. Boston Family Office LLC boosted its holdings in Pfizer by 2.4% in the fourth quarter. Boston Family Office LLC now owns 67,845 shares of the biopharmaceutical company's stock worth $1,800,000 after acquiring an additional 1,563 shares in the last quarter. Geode Capital Management LLC grew its stake in Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after acquiring an additional 2,923,537 shares during the period. StoneX Group Inc. increased its holdings in shares of Pfizer by 43.5% during the fourth quarter. StoneX Group Inc. now owns 76,031 shares of the biopharmaceutical company's stock valued at $2,017,000 after acquiring an additional 23,050 shares in the last quarter. Finally, Nemes Rush Group LLC raised its position in shares of Pfizer by 8.7% during the fourth quarter. Nemes Rush Group LLC now owns 126,861 shares of the biopharmaceutical company's stock worth $3,366,000 after purchasing an additional 10,189 shares during the period. Institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.41 during midday trading on Thursday, reaching $24.30. The company had a trading volume of 53,168,424 shares, compared to its average volume of 39,299,319. The stock has a market cap of $137.79 billion, a P/E ratio of 17.23, a P/E/G ratio of 0.64 and a beta of 0.61. The company's 50 day moving average price is $25.98 and its 200 day moving average price is $26.83. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.29 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The company's quarterly revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PFE. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Finally, Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.